NEW YORK (360Dx) — French diagnostic and theranostics firm Theradiag said on Tuesday that it has received CE marking for its Lisa Tracker drug response kit for Novartis' Cosentyx (secukinumab), a treatment for psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Lisa Tracker kits are designed to monitor serum levels of circulating TNF-alpha, prescribed TNA-alpha inhibitors, and drug neutralizing antibodies to help physicians manage treatment regimens. Cosentyx is a human monoclonal antibody that inhibits the inflammatory protein IL17A.
"With 12 tests in its Lisa Tracker range having now obtained the CE mark, Theradiag is the only company in the world to offer a monitoring test for the vast majority of biotherapies used in the treatment of autoimmune and inflammatory diseases," Theradiag Chairman Pierre Morgon said in a statement.
In September, Theradiag reported an 11 percent increase in sales of the Lisa Tracker kits for routine use in the first half of 2018.